![]() |
Toyocamycin
- 英文名称:Toyocamycin
- 品牌:WYTSCI
- 产地:进口
- 型号:1MG
- 货号:WT-AY-B10797
- cas:606-58-6
- 价格: ¥1/mg
- 发布日期: 2025-04-10
- 更新日期: 2025-05-12
产品详请
产地 | 进口 |
品牌 | WYTSCI |
货号 | WT-AY-B10797 |
用途 | 科研检测 |
英文名称 | Toyocamycin |
包装规格 | 1MG |
CAS编号 | 606-58-6 |
别名 | Toyocamycin |
纯度 | 98+% |
分子式 | |
是否进口 | 是 |
纯度:97% by TLC,;NMR (Conforms)
分子式:C12H13N5O4
分子量:291.26
溶剂:DMSO (25 mg/ml) Moderately soluble in water
性状:White or off-white solid
存储:-20°C
Activity (short version):Unfolded protein response (UPR) inhibitor
Function / Pharmacology:An adenosine analog which inhibits ribozyme self cleavage in mammalian cells, EC50 = 0.4 ?M (for expression of a luciferase reporter)1. A potent inhibitor of ER stress-induced XBP1 mRNA splicing2. It suppresses thapsigargin-, tunicamycin- and 2-deoxyglucose-induced XBP1 mRNA splicing in HeLa cells without affecting ATF6 and PERK activation. Although unable to inhibit IRE1? phosphorylation, it prevented IRE1?-induced XBP1 mRNA cleavage in vitro. It inhibits not only ER stress-induced but also constitutive activation of XBP1 expression in multiple myeloma cell lines as well as in primary patient samples2. Displays synergistic effects with bortezomib. Inhibits unfolded protein response and induces apoptosis in pancreatic cancer cells3.
分子式:C12H13N5O4
分子量:291.26
溶剂:DMSO (25 mg/ml) Moderately soluble in water
性状:White or off-white solid
存储:-20°C
Activity (short version):Unfolded protein response (UPR) inhibitor
Function / Pharmacology:An adenosine analog which inhibits ribozyme self cleavage in mammalian cells, EC50 = 0.4 ?M (for expression of a luciferase reporter)1. A potent inhibitor of ER stress-induced XBP1 mRNA splicing2. It suppresses thapsigargin-, tunicamycin- and 2-deoxyglucose-induced XBP1 mRNA splicing in HeLa cells without affecting ATF6 and PERK activation. Although unable to inhibit IRE1? phosphorylation, it prevented IRE1?-induced XBP1 mRNA cleavage in vitro. It inhibits not only ER stress-induced but also constitutive activation of XBP1 expression in multiple myeloma cell lines as well as in primary patient samples2. Displays synergistic effects with bortezomib. Inhibits unfolded protein response and induces apoptosis in pancreatic cancer cells3.